Cholestasis

Seven new ABCB11 gene mutations were identified as the likely cause of progressive familial intrahepatic cholestasis (PFIC2), according to a study that analyzed the…

It’s been a special week in our household as our daughter, Eva, started preschool. We were brimming with pride as she held her new teacher’s…

Intrahepatic cholestasis of pregnancy (ICP), the most common pregnancy-related liver disease, is significantly linked to higher rates of several maternal, fetal, and newborn issues…

A 3-year-old boy with progressive familial intrahepatic cholestasis type 3 (PFIC3) was safety and effectively treated with a liver transplant from his mother after failing…

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IN016, an experimental therapy Innorna is developing for progressive familial…

Measuring blood levels of bile acids, a component of bile, and the gamma-glutamyl transferase (GGT) enzyme may aid newborn cholestasis diagnosis by distinguishing between…

The U.S. Food and Drug Administration (FDA) has approved a label expansion for Livmarli (maralixibat) that allows the medication to be used in patients with…

Blood levels of certain fatty molecules, called short-chain fatty acids (SCFAs), in pregnant women may help diagnose intrahepatic cholestasis of pregnancy (ICP), according to…

The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to IN016, Innorna’s experimental therapy that aims to address the root…

Livmarli (maralixibat), an oral medication from Mirum Pharmaceuticals, is now approved in the European Union to treat progressive familial intrahepatic cholestasis (PFIC) in…